Commonwealth Bank of Australia Acquires 70 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Commonwealth Bank of Australia grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 970 shares of the company’s stock after purchasing an additional 70 shares during the quarter. Commonwealth Bank of Australia’s holdings in IDEXX Laboratories were worth $215,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of IDXX. Vanguard Group Inc lifted its stake in IDEXX Laboratories by 0.3% during the third quarter. Vanguard Group Inc now owns 8,918,451 shares of the company’s stock worth $2,226,581,000 after purchasing an additional 23,970 shares during the last quarter. BlackRock Inc. lifted its stake in IDEXX Laboratories by 4.6% during the fourth quarter. BlackRock Inc. now owns 6,549,022 shares of the company’s stock worth $1,218,251,000 after purchasing an additional 289,208 shares during the last quarter. Geode Capital Management LLC lifted its stake in IDEXX Laboratories by 7.6% during the fourth quarter. Geode Capital Management LLC now owns 1,162,909 shares of the company’s stock worth $215,959,000 after purchasing an additional 81,641 shares during the last quarter. Northern Trust Corp lifted its stake in IDEXX Laboratories by 2.6% during the fourth quarter. Northern Trust Corp now owns 1,056,136 shares of the company’s stock worth $196,463,000 after purchasing an additional 26,522 shares during the last quarter. Finally, MERIAN GLOBAL INVESTORS UK Ltd lifted its stake in IDEXX Laboratories by 4.4% during the fourth quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 943,305 shares of the company’s stock worth $175,473,000 after purchasing an additional 40,046 shares during the last quarter. 87.70% of the stock is currently owned by institutional investors.

NASDAQ:IDXX traded up $3.28 during trading hours on Friday, hitting $275.33. 646,056 shares of the company were exchanged, compared to its average volume of 334,034. The company has a market cap of $23.41 billion, a PE ratio of 64.63 and a beta of 0.84. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 14.81. IDEXX Laboratories, Inc. has a one year low of $176.11 and a one year high of $278.61. The business’s fifty day moving average is $259.18.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Wednesday, May 1st. The company reported $1.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.04 by $0.13. IDEXX Laboratories had a return on equity of 354,783.84% and a net margin of 17.33%. The business had revenue of $576.06 million during the quarter, compared to analyst estimates of $575.04 million. During the same period last year, the company earned $1.01 EPS. IDEXX Laboratories’s revenue for the quarter was up 7.1% compared to the same quarter last year. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 4.82 EPS for the current year.

A number of research analysts have recently commented on the company. BidaskClub upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, March 22nd. Canaccord Genuity dropped their price target on IDEXX Laboratories from $255.00 to $254.00 and set a “buy” rating for the company in a research note on Tuesday, March 26th. Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, April 3rd. Guggenheim assumed coverage on IDEXX Laboratories in a research note on Thursday, May 23rd. They issued a “buy” rating and a $276.00 price target for the company. Finally, Bank of America set a $300.00 price target on IDEXX Laboratories and gave the company a “buy” rating in a research note on Friday, June 21st. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $266.00.

In other news, VP Brian P. Mckeon sold 7,504 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $247.87, for a total value of $1,860,016.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Michael Lane sold 1,812 shares of the firm’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $245.41, for a total value of $444,682.92. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,721 shares of company stock valued at $12,554,774. Company insiders own 2.70% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Featured Article: What is a portfolio manager?

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.